

Financial Disclosure

For: Paul W. Armstrong, University Professor, University of Alberta, Edmonton, Alberta **

Updated: July, 2017

Monetary amounts are on an annual basis

Company/(Companies):	Period of Support	Name of Project	1) A research grant or contract from this Company generates revenue for the University of Alberta	2) A research grant or contract from this Company partially supports my research projects	3) Educational activities or lectures for this Company generates revenue for the University of Alberta		4) Consulting or other services for this company generates personal income		5) I receive significant personal royalties from this Company	6) I have equity in this Company	Comments
					<\$10K	>\$10K	<\$10K	>\$10K			
AstraZeneca	2015 – 2017	New Concepts in Acute Coronary Syndromes: Beyond 2000	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Merck	2015 – 2017	New Concepts in Acute Coronary Syndromes: Beyond 2000	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Merck	06/01/2016 to present	VeriCiguaT gLObal study in patients with heart failure and Reduced ejection frAction (VICTORIA)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Merck	2010 to present	Merck Advisor	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Bayer	2016 – 2017	New Concepts in Heart Failure and Atrial Fibrillation: Beyond 2000	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Bayer	2018 – 2020	A Randomized Parellel-Group, Placebo Controlled, Double-Blind, Multi-Center Confirmatory Trial to Evaluate the Efficacy and Safety of the Oral sGC Stimulator on Physical Limitations in Patients with Heart Failure and Preserved Ejection Fraction	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Bayer	2015 to 06/01/2016	VeriCiguaT gLObal study in patients with heart failure and Reduced ejection frAction (VICTORIA)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Bayer	2017 to 2019	Consultant	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Novartis	2016 – 2017	New Concepts in Heart Failure and Atrial Fibrillation: Beyond 2000	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

Company/(Companies):	Period of Support	Name of Project	1) A research grant or contract from this Company generates revenue for the University of Alberta	2) A research grant or contract from this Company partially supports my research projects	3) Educational activities or lectures for this Company generates revenue for the University of Alberta		4) Consulting or other services for this company generates personal income		5) I receive significant personal royalties from this Company	6) I have equity in this Company	Comments
					<\$10K	>\$10K	<\$10K	>\$10K			
Mast Therapeutics, Inc.	2015 to present	DSMB - Safety, Efficacy, and Pharmacokinetics of Vepoloxamer Injection, 22.5% (Sodium-Free) in Ambulatory Subjects with Chronic Heart Failure	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	DSMB
Cardiome Pharma Corp.	2016 to present	Consultant	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Sanofi-aventis Recherche & Développement	06/01/ 2012 to 03/31/ 2018	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome (ODYSSEY Outcomes)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
CSL Limited	2014 - 2016	A Phase 2b Clinical Study of CSL112, a Novel Apolipoprotein A-I Infusion Therapy Designed to Rapidly Remove Cholesterol from Arteries and Stabilize Plaque (AEGIS)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

**** Please note this document should be placed in the context that Dr. Armstrong is working 0.5 FTE at the University. In accordance with the American Heart Association conflict of interest policies.**

Column Explanations:

- (1) Funding is provided for my effort in research grants/ contracts for multi-center projects in which I serve in an executive function, this often is combined with Canadian operational responsibility. Remuneration for such work is received through Alberta Health Service in Edmonton.
- (2) A research grant from this company supports the expenses associated with projects in the Canadian VIGOUR Centre or University of Alberta that are under my direction.

- (3) I receive personal income outside of my University salary for consulting or other services (possibly including CME) from this company. The three columns represent annual payments of more or less than \$10,000 from this company.
- (4) I personally receive no royalties from any industrial firm.
- (5) Neither me nor any member of my family have equity in any industrial firm.